Azitra expands ATR-04 Phase 1/2 trial to include patients with KRAS, MEK inhibitor-related rashes

• Azitra expanded its ongoing Phase 1/2 trial of topical ATR-04 to include patients with KRAS or MEK inhibitor-associated rash.
• Eligibility now includes neurofibromatosis type 1 patients with MEK inhibitor-associated rash; shorter antibiotic and steroid washout periods aim to accelerate recruitment.
• The expansion adds treatment populations totaling approximately 85,000 U.S. patients annually, beyond approximately 220,000 receiving EGFR inhibitors.
• Previously reviewed first-cohort safety data supported the safety review committee’s recommendation to advance to the second cohort.
• The second cohort is expected to enroll approximately 24 patients receiving once-daily treatment for 28 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290830PR_NEWS_USPR_____NY84248) on October 29, 2026, and is solely responsible for the information contained therein.